Fragment-based screening targeting an open form of the SARS-CoV-2 main protease binding pocket.

3CLpro SARS-CoV-2 X-ray crystallography covalent binders fragment screening surface plasmon resonance

Journal

Acta crystallographica. Section D, Structural biology
ISSN: 2059-7983
Titre abrégé: Acta Crystallogr D Struct Biol
Pays: United States
ID NLM: 101676043

Informations de publication

Date de publication:
01 Feb 2024
Historique:
medline: 30 1 2024
pubmed: 30 1 2024
entrez: 30 1 2024
Statut: aheadofprint

Résumé

To identify starting points for therapeutics targeting SARS-CoV-2, the Paul Scherrer Institute and Idorsia decided to collaboratively perform an X-ray crystallographic fragment screen against its main protease. Fragment-based screening was carried out using crystals with a pronounced open conformation of the substrate-binding pocket. Of 631 soaked fragments, a total of 29 hits bound either in the active site (24 hits), a remote binding pocket (three hits) or at crystal-packing interfaces (two hits). Notably, two fragments with a pose that was sterically incompatible with a more occluded crystal form were identified. Two isatin-based electrophilic fragments bound covalently to the catalytic cysteine residue. The structures also revealed a surprisingly strong influence of the crystal form on the binding pose of three published fragments used as positive controls, with implications for fragment screening by crystallography.

Identifiants

pubmed: 38289714
pii: S2059798324000329
doi: 10.1107/S2059798324000329
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
ID : 4078P0_198290
Organisme : HORIZON EUROPE Marie Sklodowska-Curie Actions
ID : 884104 PSI-FELLOW-III-3i

Informations de copyright

open access.

Auteurs

Chia Ying Huang (CY)

Swiss Light Source, Paul Scherrer Institute, 5232 Villigen PSI, Switzerland.

Alexander Metz (A)

Idorsia Pharmaceuticals Ltd, 4123 Allschwil, Switzerland.

Roland Lange (R)

Idorsia Pharmaceuticals Ltd, 4123 Allschwil, Switzerland.

Nadia Artico (N)

Idorsia Pharmaceuticals Ltd, 4123 Allschwil, Switzerland.

Céline Potot (C)

Idorsia Pharmaceuticals Ltd, 4123 Allschwil, Switzerland.

Julien Hazemann (J)

Idorsia Pharmaceuticals Ltd, 4123 Allschwil, Switzerland.

Manon Müller (M)

Idorsia Pharmaceuticals Ltd, 4123 Allschwil, Switzerland.

Marina Dos Santos (M)

Idorsia Pharmaceuticals Ltd, 4123 Allschwil, Switzerland.

Alain Chambovey (A)

Idorsia Pharmaceuticals Ltd, 4123 Allschwil, Switzerland.

Daniel Ritz (D)

Idorsia Pharmaceuticals Ltd, 4123 Allschwil, Switzerland.

Deniz Eris (D)

Swiss Light Source, Paul Scherrer Institute, 5232 Villigen PSI, Switzerland.

Solange Meyer (S)

Idorsia Pharmaceuticals Ltd, 4123 Allschwil, Switzerland.

Geoffroy Bourquin (G)

Idorsia Pharmaceuticals Ltd, 4123 Allschwil, Switzerland.

May Sharpe (M)

Swiss Light Source, Paul Scherrer Institute, 5232 Villigen PSI, Switzerland.

Aengus Mac Sweeney (A)

Idorsia Pharmaceuticals Ltd, 4123 Allschwil, Switzerland.

Classifications MeSH